Status:

COMPLETED

Cardiovascular Effects of COVID-19

Lead Sponsor:

NYU Langone Health

Conditions:

COVID-19

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Cardiometabolic disease may confer increased risk of adverse outcomes in COVID-19 patients by activation of the aldose reductase pathway, a trigger of the inflammatory cascade. The study team hypothes...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Registry Study: In order to be eligible to participate in the registry study, an individual must meet all of the following criteria:
  • Age ≥18 years of age
  • Hospitalized at one of the participating NYULH locations
  • Confirmed COVID-19 infection
  • Interventional Study: In order to be eligible to participate in the registry study, and individual must meet all of the inclusion criteria of the registry study plus the following criteria:
  • Hospitalized at NYU Tisch
  • History of diabetes mellitus or blood glucose measurement \>126 mg/dl AND EITHER
  • History of hypertension and/or ischemic heart disease and/or heart failure OR
  • Other co-morbid condition that in the opinion of the PI increases risk of heart or lung injury related to the aldose reductase pathway
  • Exclusion Criteria
  • Registry Study: An individual who meets any of the following criteria will be excluded from participation in the registry study:
  • Persons who have opted out of research participation at NYU
  • Pregnancy
  • Interventional study: An individual who meets any of the following criteria will be excluded from participation in the interventional study:
  • Persons who have opted out of research participation at NYU
  • Pregnancy
  • Women of childbearing potential
  • Breast-feeding women
  • Participation in another investigational drug protocol within previous 30 days

Exclusion

    Key Trial Info

    Start Date :

    April 8 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 31 2021

    Estimated Enrollment :

    81 Patients enrolled

    Trial Details

    Trial ID

    NCT04365699

    Start Date

    April 8 2020

    End Date

    January 31 2021

    Last Update

    September 16 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    NYU Langone Health

    New York, New York, United States, 10016